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Abstract: 
Silymarin, an extract of milk thistle seeds, and silymarin-derived compounds have been 
considered hepatoprotective since the plant was first described in ancient times. 
Hepatoprotection is defined as several non-mutually exclusive biological activities including 
antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear 
evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for 
beneficial effects in humans has been equivocal. This review will summarize the current state of 
knowledge on silymarin in the context of HCV infection. The information was collated from a 
recent workshop on silibinin in Germany. 
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Introduction 
Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models 
[1], evidence for beneficial effects in humans has been equivocal. This may be attributable to a 
relative dearth of well-designed and controlled clinical trials and a generalized pervasiveness of 
inadequate attention to silymarin nomenclature and composition. The potential of silymarin-
derived natural products for hepatitis C originated from cell-culture-based studies showing that 
silymarin blocked HCV infection [2,3]. However, recent reports exemplify a bipolarity of 
silymarin action. On one hand, there is the striking observation by Ferenci et al. [4] that 
Silibinin-C-2′, 3-dihydrogen succinate, disodium salt (Legalon SIL), an intravenous, aqueous 
soluble formulation of silybin A and silybin B (synonymously called silibinin A and B; Figure 
1) that collectively comprise the mixture known as silibinin, reduces viral load in HCV-infected 
patients. This has led to other studies showing that Legalon SIL prevents re-infection of the graft 
during liver transplantation through its pretransplant antiviral effect [5–7]. At the opposite end of 
the spectrum is the report from the randomized double-blind placebo-controlled SyNCH trial 
using the highest oral doses of silymarin to date (700 mg per day) that showed lack of any 
demonstrable effect of orally administered silymarin in reduction of HCV viral loads and alanine 
aminotransferase in infected patients [8]. In the last few years, new investigators have entered the 
field with the goals of understanding how silymarin, silibinin, Legalon SIL and other silymarin-
derived flavonolignans inhibit HCV infection, as well as defining other potential clinical 
applications of Legalon SIL. 
 
Figure 1. Structures that illustrate constituents of silibinin versus Legalon SIL 
Silibinin is a mixture of silybin A and silybin B. Two succinate moieties are added synthetically 
to each individual flavonolignan to form the two-component mixture known as Legalon SIL. 
With these goals in mind, the first workshop on silibinin was held on 10 February 2012, in 
Cologne, Germany. Organized by Ralf-Torsten Pohl from Madaus Rottapharm in Cologne, 
Germany, the manufacturer of Legalon SIL, and an affiliate of the international Rottapharm-
Madaus-Group headquartered in Monza, Italy, the workshop was chaired by Peter Ferenci and 
Jean-Michel Pawlotsky, and attracted an international group of researchers in this small but 
growing field. 
History and composition of silymarin and silibinin 
Ralf Torsten-Pohl (Madaus Rottapharm) gave a brief overview of the history of silymarin and 
silibinin, stressing the ancient origins of silymarin, where the herbal extract has been referenced 
in early medical texts. He discussed briefly the taxonomy of milk thistle (Silybum marianum [L] 
Gaertn [Asteraceae]). Dr Pohl’s talk also highlighted how silymarin is extracted from the seeds 
(achenes), purified to form the mixture of the two isomeric silybin components, and then 
esterified with succinic acid to form the disuccinate disodium salt, Legalon SIL. Moreover he 
reviewed the large body of published studies on silymarin components that describe their 
pleiomorphic biological and pharmacodynamic behaviour in different preclinical and clinical 
settings covering diverse fields of medicinal use. 
Nicholas Oberlies (University of North Carolina at Greensboro, Greensboro, NC, USA) 
presented an overview of the components of silymarin, with particular emphasis on the structures 
and nomenclature of the various mixtures of flavonolignans. Focusing on the most well-studied 
mixtures, silymarin and silibinin, he compared and contrasted these through a series of structural 
diagrams, chromatograms and lists. 
The mixture silymarin constitutes major flavonolignans silybin A, silybin B, isosilybin A, 
isosilybin B, silychristin, isosilychristin and silydianin. These flavonolignans are likely derived 
from the parent flavonoid, taxifolin, which represents the left-hand side of all those compounds, 
condensing with coniferol alcohol. The various ways in which coniferyl alcohol combines with 
taxifolin imparts a fair degree of molecular diversity. By contrast, silibinin is a two-component 
mixture, made up of only silybin A and silybin B, and as noted by Pohl, Legalon SIL results 
from a synthetic addition of two succinic acid moieties to both silybin isomers. Dr Oberlies also 
showcased some of the chromatographic methods his group has developed to purify the 
individual components to >98% purity [9]. In the structural descriptions, Dr Oberlies stressed the 
importance of proper nomenclature of silymarin-derived compounds [10]. Indeed, the literature 
is rife with misnaming of compounds, and this lack of attention to detail likely adds to the 
confusion surrounding the biology of these compounds in the literature. He stressed that in the 
interest of furthering the medical potential of these compounds, scientists should strive to be 
clear, correct, and consistent in the nomenclature of silymarin-derived compounds and mixtures. 
Please refer to Table 1 for a guide to milk thistle nomenclature. 
Table 1. Milk thistle nomenclature 
Nomenclature Definition 
 Milk thistle 
extract 
The initial extract of crushed milk thistle seeds, which contains 65–80% 
silymarin and 20–35% fatty acids, such as linoleic acid. 
Silymarin A complex of ≥7 flavonolignans and 1 flavonoid that comprises 65–80% of 
milk thistle extract. 
Silibinin A semi-purified, commercially available fraction of silymarin. Silibinin was 
once thought to be a single compound and is often treated so in the literature. In 
fact, silibinin is an approximate 1:1 mixture of 2 diastereoisomeric compounds, 
silybin A and silybin B. Silybin A and B are also referred to in the literature as 
silibinin A and B. 
Legalon SIL A commercial silibinin-derived product. Flavonolignans are insoluble in 
aqueous solution. However, Legalon SIL is made soluble by converting silybin 
A and silybin B into succinate salts. Thus, Legalon SIL is an aqueous soluble 
version of silibinin that is administered intravenously. 
Flavonolignan The most common class of compound present in milk thistle extract. Milk 
thistle flavonolignans arise from a peroxidase reaction in the plant that fuses the 
flavonoid, taxifolin with coniferyl alcohol, resulting in ≥7 compounds that all 
share the same molecular weight of 482 g/mol. 
 
Human clinical experience 
Over 400 subjects have received oral silymarin in multiple clinical trials [8,11–17]. In 
approximately half of these studies, some improvement in liver histology or reduction in liver 
enzymes was observed [11–13,16]. In the HALT-C trial, approximately one-quarter of the 1,145 
patients were using silymarin at baseline [18]. In a follow-up study of 1,049 HALT-C subjects 
[19], 34% of subjects were consuming silymarin at baseline, which was associated with lower 
hepatic collagen content on study biopsies and less histological progression. However, no effect 
was seen for clinical outcomes in this study. In all studies cited above, no reduction in HCV viral 
loads was observed. 
Peter Ferenci (University of Vienna, Vienna, Austria) reviewed his pioneering studies on 
Legalon SIL administration to HCV-infected patients [4]. The first study demonstrated that 
Legalon SIL induced dose-dependent, log-fold reductions in HCV RNA level in 20 subjects. 
However, the virological response to Legalon SIL was heterogeneous from one patient to 
another. Particularly intriguing were his data showing that 2–3 weeks of daily Legalon SIL 
intravenous infusion may ‘rescue’ pegylated interferon plus ribavirin non-responders, obtaining 
40% sustained virological response rates [20]. Similar data were recently described by 
Biermer et al. [21] who also successfully rescued patients ailing on treatment with protease 
inhibitor containing triple regimes. Thus, Legalon SIL (like other inhibitors of HCV replication) 
may be interferon-sensitizing, enabling the treatment of interferon non-responders with triple 
therapy. Moreover, Legalon SIL appears to suppress viral load in patients infected with 
genotypes 1, 3 and 4, whereas the effect of Legalon SIL on genotype-2-infected patients is 
currently unknown. Dr Ferenci also reviewed the cases in which Legalon SIL prevented re-
infection of the graft following liver transplantation [5–7]. These data suggest that Legalon SIL 
may prove clinically valuable in the transplant setting, where therapeutic options are still limited. 
Mechanisms of silibinin action based on in vitro investigations 
Despite the clear reductions in viral load in HCV-infected patients treated with Legalon SIL, the 
mechanisms by which HCV suppression by silymarin, silibinin, and Legalon SIL occurs have 
not been fully characterized. In vitro studies have suggested multiple mechanisms may be 
operative. 
Abdelhakim Ahmed-Belkacem, who is in Jean-Michel Pawlotsky’s lab (INSERM U955, Henri 
Mondor University Hospital, Créteil, France), reviewed data showing that silymarin-derived 
compounds, Legalon SIL, and structurally related flavonoids can inhibit HCV RNA-dependent 
RNA polymerase (RdRp) activity in in vitro assays with recombinant HCV non-structural 5B 
(NS5B) protein with inhibitory concentrations 50% (IC50) in the range of 75–100 μM [22]. A 
focused screen of 44 compounds belonging to different subgroups of flavonoids, including 
flavones, flavonols, isoflavones, flavanols and flavonoid glycosides revealed that the flavonoid, 
quercetagetin, had the strongest RdRp inhibitory activity with IC50 of 6.7 ±1.0 μM and 4.3 ±0.7 
μM against genotype 1a H77 and genotype 1b J4 NS5B isolates, respectively. Interestingly, 
quercetagetin was fivefold less efficient against RdRp from genotype 2a strain JFH1, with an 
IC50 of 20.5 ±2.8 μM. These data suggest that Legalon SIL may differentially modulate RNA 
polymerase of different HCV genotypes. Kinetic analyses showed non-competitive inhibition 
with nucleoside triphosphates. However, although the comparisons were made on key structural 
components of highly related flavonolignans, the compared structures differ in other regions of 
the molecules. Thus, it is not clear how changes at distant molecular positions affect overall 
structure and function of flavonoids. 
Stephen J Polyak (University of Washington, Seattle, WA, USA) described the characterization 
of the hepatoprotective activities of silymarin and the seven major flavonolignans in silymarin 
using cell culture-based assays that measure antiviral, antioxidant and anti-inflammatory actions 
in liver cells, and immunomodulatory actions on T-cells [2,23]. A comparison of the effects of 
Legalon SIL versus the parent natural product mixture silibinin was also presented, focusing on 
the relationships between NS5B polymerase inhibition and antiviral activities. It was emphasized 
that Legalon SIL inhibits NS5B-1b better than silibinin, and silibinin is a poor inhibitor of 
NS5B-2a [24]. Regarding inhibition of HCV replication in subgenomic replicon cell lines, 
Legalon SIL inhibits genotype 1b but not 2a, while silibinin does not inhibit replication in 1b or 
2a replicon cell lines. Since JFH-1 infection is more effectively inhibited by silibinin than by 
Legalon SIL, the data suggest that if indeed polymerase activity is involved in suppression of 
HCV infection by Legalon SIL, there may be genotype-dependent differential susceptibilities of 
NS5B polymerases to Legalon SIL. This is in line with the NS5B polymerase inhibition study 
described by Dr Ahmed-Belkacem, although in their study, silibinin and Legalon SIL had anti-
HCV activity in both the genotype 1b subgenomic replicon and the JFH1 model [14]. These 
differences could be explained by different experimental conditions and/or cell lines. Moreover, 
Legalon SIL is by design soluble in aqueous solution while silibinin, silymarin, and all 
silymarin-derived flavonolignans are insoluble in aqueous solution and require organic solutions 
such as DMSO or methanol for solubilization. In this respect, Legalon SIL is thought to partition 
well into the membrane lipid-water interface [25]. Thus, the question arises as to whether 
differences in solubility contribute to the clear and demonstrable differences in HCV infection, 
replication, and polymerase inhibition between Legalon SIL and silibinin. 
Julie Blaising, who is in Eve-Isabelle Pécheur’s lab (UMR INSERM 1052/CNRS 5286, Lyon, 
France), presented exciting new data that continue the story on the silibinin inhibition of HCV 
entry at the fusion stage previously described by her group [3,24]. Using a variety of 
sophisticated techniques including spinning disk confocal microscopy, Ms Blaising showed that 
during HCV entry, cell culture-derived HCV virions (HCVcc) colocalize in clathrin-containing 
vesicles, and as a consequence of the interaction with vesicles that have markers of early 
endosomes, the virus particles transiently adopt low velocity movement. As the endosomes 
mature into late endosomes, the interaction with clathrin ceases, and HCVcc resume high 
velocity movement. Ms Blaising demonstrated that in presence of silibinin, HCVcc dissociation 
from clathrin vesicles does not occur, the particles become trapped in early endosomes, retain 
low velocity movement, and never become associated with late endosomes. Thus, silibinin 
inhibits key steps in the clathrin-dependent entry of HCV into hepatocytes. The data suggest that 
silibinin may impact fundamental cellular processes that could have profound influence on 
pathogens beyond HCV. These studies typify how one can use natural products or natural 
product containing mixtures to probe cellular functions to elucidate key biological processes and 
their effects on host-pathogen interactions. 
Application of HCV kinetics to understanding how Legalon SIL works 
Harel Dahari (University of Illinois, Chicago, IL, USA; Los Alamos National Laboratory, Los 
Alamos, NM, USA) reviewed the principles of mathematical modelling of HCV dynamics 
during antiviral treatment and examined the kinetics of HCV RNA changes observed during 
directly-acting antiviral (DAA) drug administration that might be relevant to understanding the 
modes of action of Legalon SIL against HCV. The original model published in 1998 [26] posits 
that HCV RNA decline is biphasic, consisting of an early, rapid phase lasting approximately 2 
days that reflects the direct antiviral effects of interferon-α (IFN) in blocking virus 
production/release. The second phase is protracted in time (days-weeks), has a slower viral RNA 
decline, and presumably reflects the loss/death of infected cells. Dr Dahari reviewed the current 
state of modelling HCV kinetics and the challenges to the original biphasic viral decline model 
that arise when fitting HCV kinetics during DAA treatment [27]. 
Jérémie Guedj (Los Alamos National Laboratory) [28] described a recent publication presenting 
a modelling analysis of HCV RNA kinetics from 25 patients infected with HCV genotype 1 or 4, 
who were treated for 7 days with monotherapy of 10, 15 or 20 mg/kg/day of Legalon SIL. Drs 
Guedj, Dahari and colleagues attempted to resolve the controversy in the field of whether 
Legalon SIL inhibits viral production, which is expected if the RdRp activity is inhibited 
[3,22,24,29], or whether Legalon SIL blocks other components of the HCV lifecycle such as 
virus entry or release [3,24]. Interestingly, the antiviral profile of Legalon SIL resembles that of 
IFN during the first phase, characterized as a rapid, dose-dependent decrease in viral RNA levels 
in serum. The second-phase decline induced by Legalon SIL is not dose-dependent and 
resembles that of an RdRp inhibitor [30]. Moreover, half of Legalon-SIL-treated patients had 
biphasic RNA decay profiles, while the other half had monophasic decay patterns. Thus, Legalon 
SIL appears to induce two classes of viral RNA decay profiles, suggesting the possibility that 
blocking both virus production/release (probably by RdRp inhibition and later steps in virion 
release) and virus entry mechanisms contribute to the anti-HCV effects of Legalon SIL. 
Pharmacokinetics and pharmacodynamics of silymarin preparations 
A recent study by Schrieber et al. [31], indicated that patients with non-alcoholic fatty liver 
disease show biphasic and in some cases triphasic plasma concentrations of silymarin 
flavonolignans. This may be due to enterohepatic recycling of silymarin flavonolignans, which 
involves the circulation of parent and conjugated (by glucuronidation and/or sulfation) versions 
of silymarin flavonolignans. The metabolized (that is, conjugated) flavonolignans are transported 
out of hepatocytes by hepatobiliary transporters into the bile. Upon encountering the small 
intestine, the parent flavonolignans can be reformed by deconjugation enzymes in intestinal 
flora. The deconjugated flavonolignans are then returned to the liver via the portal blood supply, 
where they are again taken up by hepatocytes. Thus, enterohepatic recycling can elicit profound 
differences in plasma flavonolignan pharmacokinetics, thereby influencing the hepatoprotective 
actions of Legalon SIL. Moreover, it has also been shown that patients with cirrhosis display 
higher plasma levels of silymarin flavonolignans [32]. Future studies should formally 
characterize flavonolignan metabolism following Legalon SIL versus silymarin administration. 
Key issues and areas for future research 
First, a key issue involves differences between in vitro and in vivo dosing of silymarin-derived 
compounds. The in vitro antiviral activities of silymarin and silymarin-derived flavonolignans 
are observable at concentrations generally >20 μM. In healthy subjects, oral dosing of silymarin 
results in very low plasma concentrations of major flavonolignans in the range of 50–300 ng/ml 
due to their rapid metabolism to glucuronide and sulfate conjugates [8,32–37]. The key point is 
that silymarin as an oral formulation is not highly bioavailable, with a pharmacokinetic profile 
that achieves peak plasma concentrations 1–2 h post-dosing, with elimination in 4–6 h. However, 
in HCV patients with advanced liver disease, three- to fivefold higher plasma concentrations of 
flavonolignan conjugates are achieved compared to healthy subjects [38], while in patients with 
prostate cancer, plasma levels of silybin A and B up to 40 μg/ml (approximately 80 μM) are 
achieved with high oral doses of silipide, a formulation of silibinin with phospholipids [39]. 
Thus, it is possible that with the correct formulation for oral dosing, plasma levels of 
flavonolignans that approach in vitro concentrations can be achieved. However, results from the 
SyNCH trial, which administered the highest oral doses of silymarin to date, were presented at 
the AASLD meeting in 2011 and recently published [40]. The patients achieved 2–2,000 ng/ml 
of silymarin flavonolignans and there was no significant change in serum alanine 
aminotransferase activity or RNA levels in the silymarin treatment arms [8]. While it is logical to 
assume that intravenous dosing of Legalon SIL leads to higher serum levels of silybin A and B 
as compared with oral dosing, it is not clear how much higher. Thus, there is a need for 
additional clinical trials of Legalon SIL administration to patients. The effects of Legalon SIL on 
different HCV genotypes should also be evaluated. These studies should have frequent sampling 
so that pharmacokinetic profiles can be accurately assessed. The investigators at the workshop 
also urged the company to publish existing Legalon SIL pharmacokinetic data. Although the 
SyNCH trial provided the highest oral silymarin dosing to date and was shown to be well-
tolerated and safe, it will likely be impractical to increase pill burden to increase dose in future 
studies. Therefore, improved formulations of silymarin and silibinin for oral dosing that 
overcomes the bioavailability limitations are also urgently needed. 
Second, hepatic levels of silymarin flavonolignans following oral and intravenous dosing in 
humans are unknown. Historically, liver biopsies have not been performed in patients receiving 
Legalon SIL and in the recently completed SyNCH trial [41]. However, it might be possible to 
justify studies in future trials, especially if Legalon SIL is used as a rescue therapy for previous 
non-responders to interferon-based therapies. 
Third, despite the clear antiviral effects of silymarin and silymarin-derived compounds on 
HCV in vivo and in vitro, the mechanism(s) remain incompletely understood. While polymerase 
inhibition is demonstrable in vitro using purified NS5B proteins, the activity is modest. 
Cumulatively, the data support an important role for inhibition of virus entry in inhibition of 
HCV infection. Silymarin, Legalon SIL, and silibinin also appear to inhibit release of progeny 
viruses [3,24], so it is possible that these compounds target other steps in the virus lifecycle that 
are dependent on host cell functions. Thus, additional studies should be performed to more 
clearly elucidate the mechanisms of antiviral action of silymarin. In doing so, these studies may 
reveal whether one or multiple mechanisms predominate. 
Fourth, it is not known if Legalon SIL, which is the disuccinate versions of silybin A and silybin 
B, or silybin A and silybin B are the bioactive components. It is likely that the succinate moities 
on Legalon SIL could be cleaved by intracellular esterases, meaning that the parent silybin A and 
silybin B flavonolignans are the actual intracellular biological effectors of Legalon SIL. This 
issue is quite important because if it turns out that Legalon SIL is cleaved into silybin A and 
silybin B in cells, it likely means that the bioactivity of silibinin is more relevant than that of 
Legalon SIL, and as such, this information might help to settle the controversy over antiviral 
mechanisms of action of Legalon SIL versus silibinin. The situation becomes even more 
complex considering that silymarin flavonolignans are metabolized primarily through 
glucuronidation and also by sulfation [8,42], with multiple possible sites available for 
modification on each compound. Thus, metabolic studies on liver tissue are required to resolve 
these issues. 
Fifth, Legalon SIL has shown promise in prevention of HCV infection during orthotopic liver 
transplantation [5–7]. Additional studies with recently FDA-approved protease inhibitors and 
other emerging (DAA) compounds are required to formally demonstrate the efficacy of Legalon 
SIL in conjunction with new antivirals. 
Sixth, at present, Legalon SIL is administered daily for only 1–2 weeks before treatment is 
stopped. Despite having robust anti-HCV activity, this dosing regimen could conceivably create 
a scenario for development of resistance to Legalon SIL. Indeed, a recent study shows resistance 
to SIL can be selected both in vitro and in vivo [43]; thus, further studies on SIL resistance 
should be conducted. 
With the recent approvals of new DAA compounds and second-generation drugs on the horizon, 
the renewed excitement and interest in compounds derived from the ancient botanical medicine 
known as silymarin may, at first glance, seem to be ‘too little too late’. For patients who can 
afford and tolerate standard of care therapy, this statement may be true. However, many patients 
experience side effects that require cessation of therapy, and Legalon SIL may be useful as 
salvage therapy for prior interferon non-responders. Moreover, many developing countries may 
be unable to afford DAA combination therapy, let alone pegylated interferon plus ribavirin 
therapy. Thus, silymarin-derived compounds may provide clinical utility in these situations. 
Moreover, if hepatoprotective mechanisms of action and molecular targets for silymarin 
flavonolignans can be identified, this may lead to the structure-based development of potent new 
compounds that are orally bioavailable. The efficacy of Legalon SIL in orthotopic liver 
transplantation has been demonstrated, so continued research into this area may lead to 
identification of biomarkers of silymarin treatment and efficacy, novel targets for antiviral and 
anti-inflammatory drug design, and guide refinements in natural product-derived treatments for 
liver diseases in HCV- and HCV–HIV-coinfected patients. In this regard, we have recently 
shown that Legalon SIL inhibits in vitro HIV-1 infection of multiple cell types [44]. 
Furthermore, the antioxidant and anti-inflammatory effects of silymarin [45,46] may reduce 
pathogenesis of liver diseases of non-viral origin, as well as show efficacy in inflammatory 
diseases including cancer. 
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